RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- March 01, 2007 -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it has completed the previously announced purchase of all of GlaxoSmithKline’s (NYSE: GSK) remaining options for eniluracil under the July 14, 2005 Development and License Agreement. Adherex paid GSK a fee of US$1 million in connection with the buy-out.
